Stifel Nicolaus Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)

Equities researchers at Stifel Nicolaus initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a note issued to investors on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $86.00 price target on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 278.85% from the stock’s previous close.

A number of other brokerages have also recently commented on JSPR. TD Cowen initiated coverage on shares of Jasper Therapeutics in a research report on Monday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th. Oppenheimer reiterated an “outperform” rating and issued a $80.00 target price on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Finally, Evercore ISI assumed coverage on shares of Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price target on the stock. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $67.00.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $22.70 on Thursday. The firm’s fifty day moving average price is $23.12 and its 200-day moving average price is $19.33. The stock has a market cap of $341.95 million, a P/E ratio of -4.03 and a beta of 2.24. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.23. On average, analysts predict that Jasper Therapeutics will post -4.36 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $306,000. Ikarian Capital LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,088,000. StemPoint Capital LP bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Russell Investments Group Ltd. bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $2,343,000. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $599,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.